SCHEMBL3549407

SCHEMBL3549407

O=C(O)C1(c2cccc(OCc3ccccc3)c2)N=C(N2CCOCC2)C=CN1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
PRKDC P78527 5/20 0.44
ATM Q13315 2/20 0.44
DGAT1 O75907 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NAAA Q02083 2/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
F10 P00742 1/20 0.40
EGFR P00533 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558253 0.90 ALOX5 (0.45) ALDH1A1PRKDCATMDGAT1MAPT
SCHEMBL7807445 0.70 ALDH1A1 (0.54) ALDH1A1KMT2ANAAAMAOB
SCHEMBL3553390 0.70 MEN1 (0.42) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL1263059 0.69 AGXT (0.61) ALDH1A1PRKDCATMMEN1KMT2A
SCHEMBL23163726 0.67 ADAM17 (0.57) ALDH1A1MAOB
SCHEMBL7802749 0.67 ADAM17 (0.54) ALDH1A1NAAAMAOB
SCHEMBL9217663 0.67 ALOX5 (0.61) ALDH1A1
SCHEMBL10083334 0.66 MAOB (0.57) ALDH1A1KMT2AKDM4EMAOB
SCHEMBL4599141 0.66 HSD17B10 (0.70) ALDH1A1MEN1KMT2ANAAAMAPT
SCHEMBL7810873 0.66 ALOX5 (0.67) ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042884-A1 Pharmaceutical Compounds PIK3CA, JAK1, PIK3R1 ALDH1A1 1942/4885PRKDC 2447/4885ATM 515/4885
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER NR3C1, NR4A3, NR4A1 ALDH1A1 4770/4885PRKDC 3378/4885ATM 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.